Murali V.P. Nadella

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 440 citations · Full text

Medicine, Cancer Biology, Oncology +8

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley, Patricia McCoon, Carl Cook et al. · Journal for ImmunoTherapy of Cancer · 2018 · 288 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft

Bruce E. LeRoy, Nanda K. Thudi, Murali V.P. Nadella et al. · The Prostate · 2006 · 74 citations

Medicine, Cancer Biology, Oncology +17

A novel canine lymphoma cell line: A translational and comparative model for lymphoma research

William C. Kisseberth, Murali V.P. Nadella, Matthew Breen et al. · Leukemia Research · 2007 · 50 citations

Medicine, Oncology, Veterinary Oncology +11

Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions

Nanda K. Thudi, Chelsea K. Martin, Murali V.P. Nadella et al. · The Prostate · 2008 · 49 citations · Full text

Medicine, Oncology, Pharmacology +16